Physician profile
John Fain
NPI 1033268842
$4,961.02
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,372 · 2020: $753 · 2021: $685 · 2022: $615 · 2023: $381 · 2024: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,897.36 | 2019-2024 | Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $523.86 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $491.13 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $466.00 | 2022-2024 | Infuse, Miebo |
| Aerie Pharmaceuticals, INC. | $271.89 | 2019 | |
| Glaukos Corporation | $104.85 | 2019-2022 | |
| Allergan, INC. | $46.63 | 2021-2022 | |
| Lkc Technologies, INC. | $39.22 | 2023 | |
| Eyevance Pharmaceuticals LLC | $27.57 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $22.55 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Shire North American Group INC | $19.36 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Kala Pharmaceuticals, INC. | $13.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.